Bakhu Holdings

BKUH

Drug Manufacturers - Specialty & Generic · Healthcare

Price

$0.00

+0.00 (+0.00%)

Market Cap

$301,303

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+77.0% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 170.2M (2019) → 301.3M (2023)

Bakhu Holdings is a small biotechnology company focused on cannabis-based medicines. It is developing a patented process to extract and formulate compounds from cannabis plants — such as CBD and other cannabinoids — into pharmaceutical-grade products. The company targets the medical cannabis market and aims to supply its formulations to licensed dispensaries, healthcare providers, and pharmaceutical partners.

Bakhu generates little to no revenue today, as it is still in early development and has not yet commercialized its technology at scale. It operates primarily in the United States and holds an exclusive license to its core extraction and delivery technology, which it considers its main competitive advantage. The biggest risk the company faces is the long road from development to commercial sales — it must secure regulatory approvals, find distribution partners, and raise additional capital to survive, all while competing in a crowded and heavily regulated cannabis industry.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+70.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$0/ year

Research and development spending

Insider Activity

66.2%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~1 months

$81,519 cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Bakhu Holdings has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-200.0%

Shrinking sales (-200.0% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial